Shenzhen New Industries Biomedical Engineering
Shenzhen New Industries Biomedical Engineering Co Ltd (Snibe) is a Chinese multinational medical technology and biotechnology enterprise specializing in the research, development, manufacturing, and global distribution of clinical laboratory diagnostic instruments and in vitro diagnostic (IVD) reagents, prominently featuring chemiluminescence immunoassay (CLIA) systems. The company produces fully automated chemiluminescence immunoassay analyzers and diagnostic test kits utilized in hospital laboratories for oncology, infectious disease, thyroid, and cardiac marker screening. Its core business operations encompass medical device engineering, IVD reagent synthesis, laboratory instrument manufacturing, and global wholesale distribution. Revenue is derived primarily from the global wholesale sale of diagnostic test reagents and automated laboratory analyzers to hospitals and medical laboratories. Snibe holds a leading global market position in chemiluminescence immunoassay diagnostic systems. The company is headquartered in Shenzhen, Guangdong Province, China, and its shares trade on the Shenzhen Stock Exchange.
3 of the funds FundTelligence covers report a position in Shenzhen New Industries Biomedical Engineering.
- Legal name
- Shenzhen New Industries Biomedical Engineering Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 3
Funds holding Shenzhen New Industries Biomedical Engineering
- Schroder ISF China — Schroders · 2.61 % (largest positions only, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)